Three- and Four-Laser BD FACSDiscover™ A8 Cell Analyzers Expand Accessibility of Spectral, Real‑Time Imaging Cell Analysis
FRANKLIN LAKES, N.J., Dec. 3, 2025 — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical‑technology firm, announced today the worldwide commercial launch of new configurations of its A8 cell‑analyzer platform. The instruments marry spectral flow cytometry with high‑speed imaging, aiming to lower the barrier for academic, pharmaceutical and biotech laboratories seeking deeper immunology and oncology insights.
The updated BD FACSDiscover™ A8 Cell Analyzers incorporate BD SpectralFX™ Technology, which can resolve 50 + fluorescent parameters on a single cell with high sensitivity, and BD CellView™ Image Technology, delivering sub‑second, high‑resolution images that pinpoint protein localization within individual cells. The portfolio now includes three‑laser and four‑laser variants that sit alongside the five‑laser model introduced earlier this year, giving labs a broader range of entry points based on budget and workflow demands.
“The FACSDiscover™ A8 has become the new benchmark for our core facility,” said Gert Van Isterdael, head of VIB Flow Core Ghent. “The combined spectral and imaging data streams open a dimension we didn’t have before, accelerating discovery and expanding the questions we can ask.”
From a business perspective, BD’s expansion of the A8 line reflects a strategic push into the high‑growth segment of spectral flow cytometry, a market projected to exceed $1 billion by 2027. By offering modular configurations and a flexible software‑only upgrade path for CellView™ Imaging, BD reduces upfront capital intensity while preserving a recurring‑revenue model through software licensing and consumables. This aligns with broader industry trends where laboratories favor subscription‑based financing over large CapEx outlays.
Technical analysts note that the integration of near‑infrared fluorochromes such as BD Horizon RealViolet™ 828 and RealBlue™ 824—recently added to the reagent portfolio—pushes the usable spectral bandwidth further into the NIR range. This expands the multiplexing capacity beyond traditional visible‑light panels, enabling researchers to profile complex immune phenotypes without excessive panel redesign. The capability is particularly relevant for cell‑therapy developers who must interrogate dozens of markers to characterize engineered T‑cells or NK‑cell products.
All A8 configurations feature high‑throughput, walk‑away automation that drives down the cost‑per‑insight metric, a key KPI for both academic core facilities and commercial R&D labs. The intuitive software suite supports standardized data acquisition, automated gating, and real‑time visualization, simplifying the handling of the massive datasets generated by high‑parameter experiments. Seamless integration with BD’s broader ecosystem—including the FACSDiscover™ Cell Sorters and an expanding catalog of reagents—creates a lock‑in effect that can increase customer lifetime value.
Steve Conly, worldwide president of BD Biosciences, highlighted the market impact: “In today’s research landscape, flexibility and modularity are essential. By offering multiple laser configurations and a tiered financing model, we enable organizations of any size to adopt state‑of‑the‑art flow cytometry, accelerating the pipeline from discovery to clinical translation.”
The new A8 instruments are now available through BD’s global sales network. To accommodate laboratories facing budget constraints, BD is offering flexible financing and leasing options that shift expenses from capital outlay to operational spend.
About BD
BD is a globally diversified medical‑technology company that drives innovation across diagnostics, biosciences and advanced therapeutics. With more than 70,000 employees, BD develops integrated solutions that improve patient outcomes, enhance laboratory productivity, and enable the next generation of cellular and molecular research. For additional information, visit bd.com.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/13983.html
